USFDA grants tentative approval to Lupin’s generic formulation for type 2 diabetes
时间:2024-06-26 09:24:53 阅读(143)
Global pharma major Lupin Limited on Friday announced that it has received tentative approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Dapagliflozin and Saxagliptin Tablets, 5 mg/5 mg and 10 mg/5 mg.
According to the company’s press statement, the approval has been granted to market a generic equivalent of Qtern Tablets, 5 mg/5 mg and 10 mg/5 mg of AstraZeneca AB. This product will be manufactured at Lupin’s Pithampur facility in India.
Dapagliflozin and Saxagliptin Tablets (RLD Qtern) had estimated annual sales of USD 5 million in the U.S. (IQVIA MAT November 2023).
上一篇:Share Market Highlights- Nifty settles below 19800, Sensex below 66410; Bank Nifty adds 80 points
猜你喜欢
- Switch Mobility delivers 5 e-double decker buses to Gujarat State Road Transport Corporation
- Share Market Highlights- Nifty closes below 17000, Sensex tanks 340 pts; Bank Nifty settles below 39100, Adani stocks gain
- Govt cuts import duty on refined soybean & sunflower oils to 12
- Share Market Highlights- Nifty settles below 18100, Sensex tanks 690 pts; Bank Nifty below 42670, HDFC twins fall 5%
- Tata Power, Reliance Industries, BEL, Zydus, Adani Enterprises, Axis Bank, NTPC stocks in focus
- Share Market Highlights- Nifty settles above 18300, Sensex up 180 pts; Bank Nifty above 43300, IndusInd Bank, HDFC Life gain
- SGX Nifty up- Fed outcome, global markets, Nifty view, stocks under F&O ban on F&O expiry; key things in focus
- Share Market Highlights- Sensex and Nifty ends at lower, Nifty Settles below 21,750, Sensex closes near 72,200- Auto and FMCG stocks shine
- TCS Q4 results this week- Double-digit net profit jump eyed, helped by sales, big deals; here’s what to watch